Home Neoplasma 2026 Neoplasma Vol.73, 2026, No.2, p. 75–87

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.73, 2026, No.2, p. 75–87

Title: Research progress on the role of DDR1 in cancer and targeted therapy strategy
Author: Xiaoying Guan, Yajie Zhang, Xiaoli Guan, Hong Yan

Abstract: Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by various types of collagen. Abnormal activation of DDR1 is closely related to the occurrence and development of solid tumors and plays an important role in the regulation of cell adhesion, survival, proliferation, migration, and invasion. Thus, DDR1 is a promising therapeutic target in the field of oncology. This review introduces the structural characteristics of DDR1, focusing on its role in tumor progression and related signaling pathways. It also explores the relationship between DDR1 and tumor chemotherapy resistance, and elaborates on the current research status and development prospects for inhibitors and antibodies targeting DDR1. Thus, the DDR1 inhibition strategy may serve as a new alternative for treating cancer patients.

Keywords: DDR1; cancer progression; targeted therapy; selective inhibitors
Year: 2026, Volume: , Issue: 2 Page From: 75, Page To: 87
doi:10.4149/neo_2026_251010N426


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.